Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Chlosta

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology

English

Related publications

Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013

British Journal of Haematology

Hematology

2019

English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology

English

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Hematological Oncology

English

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Hematological Oncology

English

Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease

Hematological Oncology

English

Primary Mediastinal Large B-Cell Lymphoma

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Chlosta

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Related publications

Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease

Primary Mediastinal Large B-Cell Lymphoma

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

An Ongoing Phase 1/1b Trial Investigating Novel Treatment Regimens With Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma